Serum free light chain ratio, total κ/λ ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma

Clinical Chemistry

Volumn 55, Issue 8, 2009, Pages 1510-1516

  Giarin, Manuela M ^a   Giaccone, Luisa ^a   Sorasio, Roberto ^a   Sfiligoi, Christian ^a   Amoroso, Barbara ^b   Cavallo, Federica ^a   Cipriani, Alessia ^a   Palumbo, Antonio ^a   Boccadoro, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b Binding Site Group Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MELPHALAN; PARAPROTEIN; VINCRISTINE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; COHORT ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; TREATMENT RESPONSE; WHOLE BODY RADIATION;

ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 68149132061     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.124370     Document Type: Article

References (35)

1. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R. Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680 (Pubitemid 32275810)
2. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902
3. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for the assessment of patients with Bence Jones myeloma. Lancet 2003; 361:489-491
4. Alyanakian MA, Abbas A, Delarue R, Arnulf B, Aucouturier P. Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004;75:246-248 (Pubitemid 38451104)
5. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354
6. Abraham RS, Katzmann JA, Clark RJ, Bradwell AR, Kyle RA, Gertz MA. Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Pathol 2003;119:274-278
7. Lachmann HJ, Gallimore R, Gillimore JD, Carr- Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84. (Pubitemid 36819341)
8. Bradwell AR. Serum free light measurements move to center stage. Clin Chem 2005;51:805-807
9. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-817
10. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-789
11. Dingli D, Kyle RA, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 2006;108:1979-1983 (Pubitemid 44395010)
12. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Araham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378-3383
13. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaisse E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-832 (Pubitemid 47267417)
14. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007;137:240-243 (Pubitemid 46537637)
15. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, DeGoey R, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 2008;111:4908-4915
16. Genz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79:319-328 (Pubitemid 41098849)
17. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473 (Pubitemid 44264086)
18. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003;349:26. (Pubitemid 38010075)
19. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22:1857-1868 (Pubitemid 41095176)
20. Schaar CG, Kluin-Nelemans JC, le Cessie S, Franck PF, te Marevelde MC, Wijermans PW. Early response to therapy and survival in multiple myeloma. Br J Haematol 2004;162-166
21. Harousseu JL, Attal M, Moreau P, Garban F, Facon T, Avet-Loiseu H. The prognostic impact of complete remission (CR) plus very good partial remission (VGPR) in a double-transplantation program for newly diagnosed multiple myeloma (MM): combined results of the IFM 99 Trials [Abstract]. Blood 2006;108:3077.
22. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna clinical study. J Clin Oncol 2007;25:2434-2441 (Pubitemid 46999214)
23. Dingli D, Pachero JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007;25:4933-4937 (Pubitemid 350220425)
24. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757
25. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110-1120 (Pubitemid 46425595)
26. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplantation. Br J Haematol 1998;102:1115-1123
27. Bradwell AR, Mead GP, Carr-Smith HD, eds. Serum free light chain analysis. 3rd ed. Birmingham (UK): The Binding Site Ltd; 2005. p 237.
28. Katzmann JA, Clarck RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for κ and λ immunoglobulin light chains: relative sensitivity for detection of monoclonal chains. Clin Chem 2002; 48:1437-1444 (Pubitemid 34925779)
29. Aguzzi F, Gasparro C, Bergami MR, Rizzotti P, Busco F. Italian interlaboratory evaluation of kappa/ lambda ratio and immunoglobulin assay on the Beckman Array Protein System. Giorn It Chim Clin 1991;16:323-328
30. Napoli P, Battaglio S, Astorino D, Di Bello C, Tortarolo S, Boccadoro M. Messa a punto di una metodica di immunofissazione ad alta risoluzione sul sistema Hydrasis Sebia [Abstract]. Biochem Clin 2000;24:M012.
31. Cox DR. Regression models and life-tables (with discussion). J R Static Soc 1972;24:187-220.
32. Lahuerta JJ, Manteos MV, Martìnez-Lòpez J, Rosinõl L, Sureda A, de la Rubia J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008;26:5775-5782
33. Morgan GJ, Davies FE, Owen RG, Rawstron AC, Bell S, Cocks K, et al. Thalidomide combinations improve response rates: results from the MRC IX study [Abstract]. Blood 2007;110:1051a.
34. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Soppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 2006;9:1498-1505 (Pubitemid 44736116)
35. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179-1184 (Pubitemid 47502875)